Taysha Gene Therapies (TSHA) director Long received 21,335 shares
Insider transactions reported
Alison S Long (director at Taysha Gene Therapies Inc., TSHA) reported that they received 21,335 shares on Jun 1, 2026. After these transactions the filing shows 127,178 shares held directly.
- Reporting person
- Long Alison S
| Date | Type | Security | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|
| Jun 1, 2026 | Grant or award (A) | Common Stock1 | +21,335 | - | - | 127,178 direct |
Options and other derivatives
| Date | Type | Security | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|
| Jun 1, 2026 | Grant or award (A) | Stock Option (right to buy)On 42,671 Common Stock2 | +42,671 | - | - | 42,671 direct |
Holdings before and after
- Common Stock: 105,843 to 127,178 direct
- Stock Option (right to buy): 0 to 42,671 direct
Footnotes from the filing
- 1. Represents a restricted stock unit ( RSU ) award. The RSUs will vest on the earlier of June 1, 2027 or the next annual stockholders meeting, subject to the Reporting Person's continued service as a director through the applicable vesting date.
- 2. The shares vest on the earlier of June 1, 2027 or the next annual stockholders meeting, subject to the Reporting Person's continued service as a director through the applicable vesting date.
Transaction codes in this filing
- Grant or award:
- Code A marks a grant or award from the company under an exempt employee or director plan. Usually nothing is paid for it.
FAQ
What did Long report in this TSHA Form 4?
Alison S Long (director at Taysha Gene Therapies Inc., TSHA) reported that they received 21,335 shares on Jun 1, 2026. After these transactions the filing shows 127,178 shares held directly.
How many TSHA shares does Long hold after this filing?
The filing shows 127,178 shares held directly after the reported transactions. Form 4 reports only the positions it lists, so this may not be every holding.
What does transaction code A mean on an SEC Form 4?
Code A marks a grant or award from the company under an exempt employee or director plan. Usually nothing is paid for it.
Historical context for TSHA
Across the 14 sessions after earlier TSHA headlines, the stock closed higher 11 times and lower 3 times, with a median move of 3.4% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | TSHA | SPY |
|---|---|---|---|
| May 6, 2026 | Taysha Gene Therapies Reports First Quarter 2026 Financial Results and Provides Corporate Update | +0.6% | +1.4% |
| May 4, 2026 | Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | +4.9% | -0.4% |
| Apr 29, 2026 | Taysha Gene Therapies to Release First Quarter 2026 Financial Results and Host Conference Call and Webcast on May 6 | -0.5% | -0.0% |
| Apr 28, 2026 | Taysha Gene Therapies to Present New Preclinical Data Supporting Construct Design of TSHA-102 for Rett Syndrome at the ASGCT 2026 Annual Meeting | -2.5% | -0.5% |
| Apr 6, 2026 | Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | +6.4% | +0.5% |
| Mar 19, 2026 | Taysha Gene Therapies Reports Full-Year 2025 Financial Results and Provides Corporate Update | +2.5% | -0.2% |
Earlier insider filings at TSHA
- Jun 2, 2026Director Donenberg Phillip B. was granted 21,335 shares, increasing direct ownership by 10% to 241,289 units (SEC Form 4)
- Apr 13, 2026SEC Form 4 filed by Nagendran Sukumar
- Feb 6, 2026CHIEF FINANCIAL OFFICER Alam Kamran sold $7,481 worth of shares (1,655 units at $4.52), decreasing direct ownership by 0.11% to 1,442,131 units (SEC Form 4)
- Jan 27, 2026President and Head of R&D Nagendran Sukumar sold $547,469 worth of shares (116,050 units at $4.72), decreasing direct ownership by 8% to 1,317,389 units (SEC Form 4)
- Jan 27, 2026Chief Executive Officer Nolan Sean P. sold $840,196 worth of shares (178,101 units at $4.72), decreasing direct ownership by 6% to 2,908,257 units (SEC Form 4)
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Listed since
- 2020
Follow TSHA and get a push notification the moment its next story breaks.